Ronald J. Buckanovich, MD, PhD, of the University of Michigan, discusses study findings on health-related quality of life with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer. (Abstract 5507)
Tanya B. Dorff, MD, of the USC Norris Comprehensive Cancer Center, and Sumanta K. Pal, MD, of the City of Hope, discuss two key presentations on prostate cancer: findings on adding abiraterone for men with high-risk prostate cancer starting long-term androgen-deprivation therapy, and an after-market study on continuing enzalutamide post PSA progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer. (Abstracts LBA5003, 5004)
Lisa A. Carey, MD, of the University of North Carolina, and Mark E. Robson, MD, of Memorial Sloan Kettering Cancer Center, discuss phase III study findings on olaparib monotherapy vs chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation. (Abstract LBA4)
Solange Peters, MD, PhD, of the University of Lausanne, who has been a driving force in ESMO’s efforts to promote women in oncology, talks with Mary Gospodarowicz, MD, of Princess Margaret Hospital, a recipient of the 2017 Women Who Conquer Cancer Mentorship Award.
Greta Stifel recounts her story about a misdiagnosed tumor and urges physicians to raise awareness of neuroendocrine disease.
Ronald J. Buckanovich, MD, PhD, of the University of Michigan, discusses study findings on chemotherapy and cediranib in relapsed ovarian cancer. (Abstract 5506)
